​

Sera Prognostics Stock (NASDAQ:SERA)

ForecastRevenueOwnershipFinancialsChartTranscripts
Sera Prognostics by TradingView

Previous Close

$3.40

52W Range

$1.37 - $9.13

50D Avg

$3.18

200D Avg

$2.95

Market Cap

$130.57M

Avg Vol (3M)

$44.33K

Beta

0.98

Div Yield

-

SERA Company Profile

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

63

IPO Date

Jul 15, 2021

Website

SERA Performance

SERA Financial Summary

Dec 24Dec 23Dec 22
Revenue$77.00K$306.00K$268.00K
Operating Income$-36.63M$-39.82M$-45.65M
Net Income$-32.90M$-36.24M$-44.25M
EBITDA$-36.63M$-35.29M$-42.91M
Basic EPS$-0.99$-1.16$-1.43
Diluted EPS$-0.99$-1.16$-1.43

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 13, 25 | 5:00 PM
Q2 25Aug 07, 25 | 5:00 PM
Q1 25May 11, 25 | 5:00 PM

Peer Comparison

TickerCompany
RPIDRapid Micro Biosystems, Inc.
SRZNSurrozen, Inc.
TVGNTevogen Bio Holdings Inc.
APYXApyx Medical Corporation
HURATuHURA Biosciences, Inc.
CGTXCognition Therapeutics, Inc.
ONCYOncolytics Biotech Inc.
STSSSharps Technology, Inc.
LUCDLucid Diagnostics Inc.
ATOSAtossa Therapeutics, Inc.